It have been reported that DCs migrate into tumor-draining lymph nodes and prime CD8+ or CD4+ T cells to induce antitumor responses in mouse models, although their manipulation in cancer vaccination protocols has not reached a potent clinical impact43,44. This evidence concerns the gene CD4 and cancer.